Assignee
BRAHMS GMBH
DE·43 granted patents·33 pending applications·106 citations·filing 2003–2025
Top patents by PatentIndex Score
76 records- 0194US9753039B2Prognosis of adverse events in patients with suspected chronic heart failureBRAHMS GMBH·Filed 2016·Granted Sep 5, 2017·6 cites·20 claims
- 0294US8354506B2Antibodies for the selective determination of procalcitonin 1-116BRAHMS GMBH·Filed 2008·Granted Jan 15, 2013·21 cites·4 claims
- 0393US9541549B2Determination of a midregional proadrenomedullin partial peptide in biological fluids for diagnostic purposes, and immunoassays for carrying out such a determinationBRAHMS GMBH·Filed 2014·Granted Jan 10, 2017·9 cites·5 claims
- 0492US7972799B2Method for determining sepsis using pro-ADMBRAHMS GMBH·Filed 2009·Granted Jul 5, 2011·14 cites·10 claims
- 0591US7915002B2Method for controlling the therapy of patients suffering from cardiac insufficiency by means of in vitro determination of threshold values of vasoactive peptidesBRAHMS GMBH·Filed 2007·Granted Mar 29, 2011·17 cites·13 claims
- 0690US11241395B2Use of procalcitonin (PCT) in risk stratification and prognosis of patients with a primary, non-infectious diseaseBRAHMS GMBH·Filed 2019·Granted Feb 8, 2022·2 cites·10 claims
- 0788US8013123B2Use of precursors of enkephalins and/or their fragments in medical diagnosticsBRAHMS GMBH·Filed 2005·Granted Sep 6, 2011·9 cites·5 claims
- 0884US9513301B2Method for risk stratification in stable coronary artery diseaseBRAHMS GMBH·Filed 2015·Granted Dec 6, 2016·2 cites·2 claims
- 0984US7998686B2Method for determining sepsis using pro-BNPBRAHMS GMBH·Filed 2008·Granted Aug 16, 2011·4 cites·11 claims
- 1081US8383332B2Procalcitonin for the diagnosis of bacterial infections and guidance of antibiotic treatment in patients with acute stroke or transient ischemic attackBRAHMS GMBH·Filed 2010·Granted Feb 26, 2013·5 cites·21 claims
- 1179US10048280B2Immunoassay for the detection of procalcitoninBRAHMS GMBH·Filed 2017·Granted Aug 14, 2018·1 cites·9 claims
- 1278US2024393352A1Antibiotic therapy guidance based on procalcitonin in patients with comorbiditiesBRAHMS GMBH·Filed 2024·Application pending·0 cites
- 1376US8853355B2Diagnosis and risk stratification by determining the marker CT-proADMBRAHMS GMBH·Filed 2013·Granted Oct 7, 2014·1 cites·14 claims
- 1474US12405279B2Method for preparing a sampleBRAHMS GMBH·Filed 2022·Granted Sep 2, 2025·0 cites·17 claims
- 1574US12000845B2Method for discharging a patient from an intensive care unitBRAHMS GMBH·Filed 2022·Granted Jun 4, 2024·0 cites·10 claims
- 1673US11041867B2ProADM and/or histones as markers indicating an adverse eventBRAHMS GMBH·Filed 2018·Granted Jun 22, 2021·2 cites·9 claims
- 1773US7977072B2Sandwich immunoassay for identifying partial proANP peptidesBRAHMS GMBH·Filed 2003·Granted Jul 12, 2011·10 cites·7 claims
- 1872US9664689B2Method for the selective detection and measurement of procalcitonin 1-116 and amino-terminal peptides of procalcitonin comprising amino acids 1 and 2 of procalcitonin 1-116BRAHMS GMBH·Filed 2013·Granted May 30, 2017·1 cites·7 claims
- 1972US9488659B2Prognosis of adverse events in patients with suspected chronic heart failureBRAHMS GMBH·Filed 2013·Granted Nov 8, 2016·1 cites·17 claims
- 2071US10067063B2Prognosis and risk assessment in stroke patients by determining the level of marker peptidesBRAHMS GMBH·Filed 2013·Granted Sep 4, 2018·1 cites·9 claims
- 2169US10857129B2V1B receptor antagonist for use in the treatment of patients having an elevated AVP level and/or an elevated copeptin levelBRAHMS GMBH·Filed 2019·Granted Dec 8, 2020·0 cites·7 claims
- 2269US2025369987A1Prescription of remote patient management based on biomarkersBRAHMS GMBH·Filed 2025·Application pending·0 cites
- 2368US9726675B2Diagnosis and risk stratification by determining the marker CT-proADMBRAHMS GMBH·Filed 2014·Granted Aug 8, 2017·0 cites·19 claims
- 2467US2019041408A1Immunoassay for the detection of procalcitoninBRAHMS GMBH·Filed 2018·Application pending·0 cites
- 2565US12153057B2Antibiotic therapy guidance based on procalcitonin in patients with comorbiditiesBRAHMS GMBH·Filed 2018·Granted Nov 26, 2024·0 cites·15 claims
- 2665US2018052179A1Risk assessment for antibiotics treatment in patients suffering from primary non-infectious disease by determining the level of procalcitoninBRAHMS GMBH·Filed 2017·Application pending·0 cites
- 2765US2018143190A1Determination of a midregional proadrenomedullin partial peptide in biological fluids for diagnostic purposes, and immunoassays for carrying out such a determinationBRAHMS GMBH·Filed 2018·Application pending·0 cites
- 2864US11327082B2Proadrenomedullin as a marker for abnormal platelet levelsBRAHMS GMBH·Filed 2018·Granted May 10, 2022·0 cites·29 claims
- 2964US10954298B2Method of obtaining a binder to prepro-vasopressin or fragments thereofBRAHMS GMBH·Filed 2018·Granted Mar 23, 2021·0 cites·2 claims
- 3064US10718783B2Diagnosis and risk stratification of infections and chronic diseases of the respiratory tract and lungs by means of provasopressin, particularly copeptin or neurophysin IIBRAHMS GMBH·Filed 2016·Granted Jul 21, 2020·0 cites·7 claims
- 3163US2017370940A1Prognosis of adverse events in patients with suspected chronic heart failureBRAHMS GMBH·Filed 2017·Application pending·0 cites
- 3263US2025035646A1Biomarkers for prognosis of early onset preeclampsiaBRAHMS GMBH·Filed 2022·Application pending·0 cites
- 3363US2017242037A1Diagnostic method for disorders using copeptinBRAHMS GMBH·Filed 2017·Application pending·0 cites
- 3462US10254289B2In vitro method for early or differential diagnosis or prognosis of myocardial infarction in a patientBRAHMS GMBH·Filed 2016·Granted Apr 9, 2019·0 cites·12 claims
- 3562US9261517B2Diagnosis of acute coronary syndrome, myocardial infarction, or angina pectoris by means of neurophysin IIBRAHMS GMBH·Filed 2013·Granted Feb 16, 2016·0 cites·9 claims
- 3661US11835531B2Procalcitonin for the prognosis of adverse eventsBRAHMS GMBH·Filed 2019·Granted Dec 5, 2023·0 cites·4 claims
- 3761US9810699B2Risk assessment for antibiotics treatment in patients suffering from primary non-infectious disease by determining the level of procalcitoninBRAHMS GMBH·Filed 2015·Granted Nov 7, 2017·0 cites·17 claims
- 3861US9217742B2Method for risk stratification in stable coronary artery diseaseBRAHMS GMBH·Filed 2014·Granted Dec 22, 2015·0 cites·2 claims
- 3961US2011263821A1Prognosis and risk assessment in stroke patients by determining the level of marker peptidesBRAHMS GMBH·Filed 2009·Application pending·0 cites
- 4059US12517138B2Method for guidance of fluid therapy based on proadrenomedullinBRAHMS GMBH·Filed 2018·Granted Jan 6, 2026·0 cites·15 claims
- 4159US12442825B2Prescription of remote patient management based on biomarkersBRAHMS GMBH·Filed 2020·Granted Oct 14, 2025·0 cites·20 claims
- 4256US2016161505A1DIAGNOSIS AND RISK STRATIFICATION USING NT-proET-1BRAHMS GMBH·Filed 2016·Application pending·0 cites
- 4355US2021285968A1Proadm and/or histones as markers indicating an adverse eventBRAHMS GMBH·Filed 2021·Application pending·0 cites
- 4455US2016169912A1Diagnosis and Risk Assessment of Pancreatic Diabetes Using MR-proADMBRAHMS GMBH·Filed 2016·Application pending·0 cites
- 4553US8029790B2Monoclonal thyroid stimulating or blocking antibodies, peptide sequences corresponding to their variable regions, and their uses in diagnostic, preventive and therapeutic medicineBRAHMS GMBH·Filed 2005·Granted Oct 4, 2011·0 cites·2 claims
- 4653US2025189539A1Sample including pro-adm as a therapy monitoring marker for critcally ill patientsBRAHMS GMBH·Filed 2025·Application pending·0 cites
- 4753US2014335628A1Method of obtaining a binder to prepro-vasopressin or fragments thereofBRAHMS GMBH·Filed 2012·Application pending·0 cites
- 4853US2015192595A1Methods of diagnosis and risk stratification of adverse events in post myocardial infarction patients using pro-adrenomedullinBRAHMS GMBH·Filed 2015·Application pending·0 cites
- 4952US2011262939A1Methods and assays for classifying foodstuff and/or beverage and/or diet and/or nutrition regimen and/or medicament in view of an effect on the cardiovascular systemBRAHMS GMBH·Filed 2009·Application pending·0 cites
- 5052US2011111526A1Pro-endothelin-1 for the prediction of impaired peak oxygen consumptionBRAHMS GMBH·Filed 2009·Application pending·0 cites
Showing the top 50 of 76 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →